Research presentation
Clearing the Bottleneck: How Digital Innovation is Driving Clinical Trials
Clinical trials—the backbone of drug development—are finally being rewritten by digital innovation. From AI-driven design to decentralised, patient-centric models, technology is slashing timelines, cutting costs, and widening access. Yet funding for these ventures has plunged 46% in five years, just as demand for faster, smarter R&D reaches record highs. This report unpacks how startups, investors, and pharma can seize the opportunity to turn the industry’s biggest bottleneck into its most powerful accelerator.
About this report
Digital Innovation in Clinical Trials: Turning R&D’s Biggest Bottleneck into an Accelerator
Clinical trials—the foundation of drug development—are being fundamentally reimagined. What was once a rigid, manual, and resource-intensive process is now entering an era of intelligent automation and patient-centric design. Artificial intelligence, data integration, and decentralised trial models are transforming how therapies move from discovery to approval, dramatically reducing timelines, costs, and patient burden.
Yet this transformation comes with a paradox: while the demand for faster, smarter, and more inclusive R&D has never been higher, investment in digital clinical trial ventures has dropped sharply—down 46% over the past five years. This contraction in funding threatens to stall innovation at the precise moment it is most needed.
Galen Growth’s latest thematic report—Clearing the Bottleneck: How Digital Innovation is Driving Clinical Trials—unpacks the data behind this shift. Leveraging HealthTech Alpha’s proprietary venture intelligence, the report identifies how startups, investors, and pharmaceutical leaders can convert the industry’s most persistent bottleneck into its most powerful accelerator.
It explores the rise of AI-driven protocol design, adaptive patient recruitment powered by real-world data, and decentralised trial models that extend participation beyond traditional sites. It also examines how venture and corporate investors—from GV to McKesson Ventures and Merck GHI—are recalibrating their portfolios toward AI-enabled technologies that boost precision, scalability, and regulatory confidence.
H1 2025 Digital Health Funding Highlights from Europe
-
Clinical Trials remains one of the smallest Digital Health clusters, accounting for only 3% of global ventures.
-
Funding has fallen 46% over five years, even as pressure mounts to deliver faster, lower-cost R&D.
-
99% of 2025 funding within this cluster has gone to AI-powered ventures, underscoring a clear shift toward automation and intelligence.
-
17% of all digital health exits originate from clinical-trial technologies—the highest share across any category, reflecting strong acquisition interest.
-
Only 10% of ventures founded in the past five years have successfully reached a Series A round, revealing both opportunity and risk in a market undergoing consolidation.
Ventures and Companies Covered in the Report
Pathos • Lindus Health • N-Power Medicine • Mural Health • Paradigm • Lightship • Autonomize AI • Motivity • Transcarent • Citizen Health • SeqOne Genomics • Science Corporation • Trialbee • Merck Global Health Investment Fund (GHI) • McKesson Ventures • GV • Khosla Ventures • Lux Capital
About the Data
The report is powered by HealthTech Alpha, the premier digital health intelligence platform delivering unparalleled data and insights into the evolving healthcare technology landscape. Leveraging an extensive database of over 16,000 ventures and cutting-edge analytics, HealthTech Alpha provides a data-driven foundation to analyse the critical trends shaping the future of digital health.
Designed to empower stakeholders—including investors, pharmaceutical leaders, and medical device manufacturers—HealthTech Alpha offers actionable intelligence to navigate digital transformation complexities. This collaboration ensures readers gain a comprehensive, evidence-based view of the intersection between digital health and healthcare, equipping them to identify strategic opportunities, assess market dynamics, and stay ahead in this fast-evolving industry.
Download and define the next step
Get the deck, then turn the Clinical Trials insight into a brief
Use the Get the presentation button when you are ready to open the access form. The Brief Builder stays in focus here so your team can describe the decision, output, and scope you need from Galen Growth before starting the conversation.
Answer three prompts to shape the follow-up work.
1. What decision are you trying to make?
2. What output would be most useful?
3. What scope should we prioritize?
Next step
Want the analysis behind the slides?
Tell us what decision you are trying to make. We can shape the data, company universe, and strategic interpretation around your market, portfolio, partnership, or investment question.
